Phase 2b vitiligo top-line results expected in mid-2025VYN202 Phase 1b psoriasis trial initiated with results anticipated ...
Q4 2024 Earnings Call Transcript March 5, 2025 Kamada Ltd. beats earnings expectations. Reported EPS is $0.07, expectations ...
Q4 2024 Earnings Call Transcript March 5, 2025 EyePoint Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.64 EPS, expectations were $-0.54. Tessa Romero – JPMorgan: Yigal ...
RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”) is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies ...
Morgan Stanley Direct Lending Fund offers a 10% dividend yield and a low-risk business model. See why I continue to rate MSDL a buy.
First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-? (FR?) and ZW171, a bispecific 2 + 1 T cell engager (TCE) targeting mesothelin ...
VOQUEZNA® (vonoprazan) generated $55.3 million in 2024 net revenues in its first full year of launch, driven by strong demand, including $29.7 ...
High-yielding investments amid market volatility include Energy Transfer (7% yield) & Starwood Property Trust (9.7% yield).
12h
Kamada Ltd (KMDA) reports a 13% revenue increase and unveils plans for biosimilar launches and plasma center expansions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback